Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469514 | 0.92 | TTK (0.48) | MAOBPDE3BPDE3AFLT3TTK | |
| SCHEMBL17469501 | 0.90 | FLT3 (0.41) | MAOBMAOAFLT3TTKMAPK8 | |
| SCHEMBL17465767 | 0.90 | TTK (0.50) | MAOBFLT3TTKMAPK8 | |
| SCHEMBL17469475 | 0.86 | HTR1D (0.46) | MAOBFLT3TTKCARM1PRMT1 | |
| SCHEMBL17469492 | 0.84 | PARP10 (0.43) | MAOBFLT3TTKMAPK8CARM1 | |
| SCHEMBL17469455 | 0.84 | CARM1 (0.39) | MAOBMAOAFLT3TTKCARM1 | |
| SCHEMBL17469472 | 0.83 | MAOB (0.46) | MAOBMAOACARM1PRMT1 | |
| SCHEMBL19245440 | 0.83 | TTK (0.50) | FLT3TTKMAPK8 | |
| SCHEMBL16129425 | 0.83 | HDAC6 (0.42) | MAOBMAOACARM1PRMT1 | |
| SCHEMBL16129426 | 0.82 | FGFR4 (0.49) | MAOBMAOATTKCARM1PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | MAOB 382/4885MAOA 549/4885PDE3B 172/4885 |
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | MAOB 382/4885MAOA 549/4885PDE3B 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.